Peripheral Markers of Depression

Nobis, Aleksander, Zalewski, Daniel, Waszkiewicz, Napoleon·2020·Journal of Clinical Medicine
DOI 10.3390/jcm9123793

Cites (457)

Items 401–451 of 451

  1. Morning and nocturnal serum melatonin rhythm levels in patients with major depressive disorder: an analytical cross-sectional study
    Shahnaz Khaleghipour, Mohsen Masjedi, Hassan Ahade, Meersalahodin Enayate, Gholamreza Pasha, Farah Nadery, Gholamhossien Ahmadzadeh · 2012 · Sao Paulo Medical Journal
  2. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report
    William Victor Bobo, Helen Chen, Madhukar H. Trivedi, Jonathan W. Stewart, Andrew Alan Nierenberg, Maurizio Fava M. D, Benji T. Kurian, Diane Warden, David W. Morris, James F. Luther et al. · 2011 · Journal of Affective Disorders
  3. Phospholipid metabolism and depression: the possible roles of phospholipase A2 and coenzyme A‐independent transacylase
    David F. Horrobin · 2001 · Human Psychopharmacology Clinical and Experimental
  4. Potential clinical utility of plasma amino acid profiling in the detection of major depressive disorder
    Hongbo Xu, Liang Fang, Zicheng Hu, Yi‐Chen Chen, Jianjun Chen, Fangfang Li, Jia Yi Lu, Jun Mu, Peng Xie · 2012 · Psychiatry Research
  5. An Evolutionary Hypothesis of Depression and Its Symptoms, Adaptive Value, and Risk Factors
    Dennis K. Kinney, Midori Tanaka · 2009 · The Journal of Nervous and Mental Disease
  6. An IgM-mediated immune response directed against nitro-bovine serum albumin (nitro-BSA) in chronic fatigue syndrome (CFS) and major depression: evidence that nitrosative stress is another factor underpinning the comorbidity between major depression and CFS.
    Michael H. J. Maes, Ivana Mihaylova, Marta Kubera, Jean–Claude Leunis · 2008 · PubMed
  7. Significantly Higher Peripheral Insulin-Like Growth Factor-1 Levels in Patients With Major Depressive Disorder or Bipolar Disorder Than in Healthy Controls
    Kun-Yu Tu, Ming‐Kung Wu, Yen‐Wen Chen, Pao‐Yen Lin, Hung‐Yu Wang, Ching-Kuan Wu, Ping‐Tao Tseng · 2016 · Medicine
  8. Alterations in leukocyte transcriptional control pathway activity associated with major depressive disorder and antidepressant treatment
    Synthia H. Mellon, O.M. Wolkowitz, Marcus D. Schonemann, Elissa S. Epel, Rebecca Rosser, H B Burke, Laura Mahan, Victor I. Reus, Dimitri Stamatiou, C -C Liew et al. · 2016 · Translational Psychiatry
  9. Metabolomic biosignature differentiates melancholic depressive patients from healthy controls
    Yashu Liu, Lynn Yieh, Tao Yang, Wilhelmus H. I. M. Drinkenburg, Pieter Johan Peeters, Thomas Steckler, Vaibhav A. Narayan, Gayle M. Wittenberg, Jieping Ye · 2016 · BMC Genomics
  10. Ibuprofen ameliorates fatigue- and depressive-like behavior in tumor-bearing mice
    Diana M. Norden, Donna O. McCarthy, Sabahattin Bicer, Raymond D. Devine, Peter J. Reiser, Jonathan P. Godbout, Loren E. Wold · 2015 · Life Sciences
  11. Stability of plasma GABA at four-year follow-up in patients with primary unipolar depression
    Frederick Petty, Gerald L. Kramer, Mark Fulton, Lori L. Davis, Augustus John Rush · 1995 · Biological Psychiatry
  12. Pterin metabolism in depression: an extension of the amine hypothesis and possible marker of response to ECT
    David N. Anderson, Mohammed T. Abou‐Saleh, James Collins, Kevin R. Hughes, Richard J. Cattell, C.G.B. Hamon, J. Anthony Blair, Michael E. Dewey · 1992 · Psychological Medicine
  13. Depression and Cardiovascular Disease: Role of Nitric Oxide
    Vivian Liane Mattos Pinto, Tatiana M.C. Brunini, Marcos Ferraz, Anicet Okinga, Antônio Claúdio Mendes‐Ribeiro · 2008 · Cardiovascular & Hematological Agents in Medicinal Chemistry
  14. Oxidative stress predicts depressive symptom changes with omega-3 fatty acid treatment in coronary artery disease patients
    Graham Mazereeuw, Nathan Herrmann, Ana C. Andreazza, Gustavo Scola, David W.L., PAUL I. OH, Krista L. Lanctôt · 2016 · Brain Behavior and Immunity
  15. Roles of exogenous and endogenous FGF-2 in animal models of depression
    J. Jarosik, Beata Legutko, Sabine Werner, Klaus Unsicker, Oliver von Bohlen und Halbach · 2011 · Restorative Neurology and Neuroscience
  16. Risk assessment and predicting outcomes in patients with depressive symptoms: a review of potential role of peripheral blood based biomarkers
    Bhautesh Jani, Gary McLean, Barbara I. Nicholl, Sarah Barry, Naveed A. Sattar, Frances S Mair, Jonathan Cavanagh · 2015 · Frontiers in Human Neuroscience
  17. Biomarker-based subtyping of depression and anxiety disorders using Latent Class Analysis. A NESDA study
    Lian Beijers, Klaas J. Wardenaar, Fokko J. Bosker, Femke Lamers, Gerard van Grootheest, Marrit K. de Boer, Brenda W.J.H. Penninx, Robert A. Schoevers · 2018 · Psychological Medicine
  18. Indoleamine 2,3-dioxygenase--a new antioxidant enzyme.
    Yi Sun · 1991 · PubMed
  19. Is major depressive disorder a metabolic encephalopathy?
    Brian Herbert Harvey · 2008 · Human Psychopharmacology Clinical and Experimental
  20. Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopram
    Per Svenningsson, Louise Berg, D Matthews, D. Ionescu, Erica M. Richards, Mark J. Niciu, A Malinger, Madeleine M. Toups, Husseini K. Manji, Madhukar H. Trivedi et al. · 2014 · Molecular Psychiatry
  21. Dysregulation of leukocyte gene expression in women with medication-refractory depression versus healthy non-depressed controls
    Eli Iacob, Kathleen C. Light, Scott C. Tadler, Howard R. Weeks, Andrea T. White, Ronald W. Hughen, Timothy A. VanHaitsma, Lowry Bushnell, Alan R. Light · 2013 · BMC Psychiatry
  22. Lipid Peroxidation and Depressed Mood in Community-Dwelling Older Men and Women
    Yuri Milaneschi, Matteo Cesari, Eleanor Marie Simonsick, Nicole Vogelzangs, Alka M. Kanaya, Kristine S. Yaffe, Paola Patrignani, Andrea L. Metti, Stephen B. Kritchevsky, Marco Pahor et al. · 2013 · PLoS ONE
  23. Biological role of the soluble interleukin-2 receptor in sarcoidosis.
    Remi M. M. Vanmaris, Ger T. Rijkers · 2017 · Sarcoidosis vasculitis and diffuse lung diseases
  24. Significantly decreased mRNA levels of BDNF and MEK1 genes in treatment-resistant depression
    W. Hong, Jin-Bo B. Fan, Chengmei Yuan, Chen Zhang, Yingyan Hu, Dai-Hui Peng, Yong Wang, Jia Huang, Ze-Zhi Li, Shun-Ying Yu et al. · 2014 · NeuroReport
  25. Significantly higher peripheral fibroblast growth factor-2 levels in patients with major depressive disorder
    Ching-Kuan Wu, Ping‐Tao Tseng, Yen‐Wen Chen, Kun-Yu Tu, Pao‐Yen Lin · 2016 · Medicine
  26. Finding a biosignature for melancholic depression
    Claire V. Day, Leanne Maree Williams · 2012 · Expert Review of Neurotherapeutics
  27. VGF, a New Player in Antidepressant Action?
    Jessica E. Malberg, Lisa M. Monteggia · 2008 · Science Signaling
  28. The Interdependence of Subtype and Severity: Contributions of Clinical and Neuropsychological Features to Melancholia and Non-melancholia in an Outpatient Sample
    Candice R Quinn, Anthony W.F. Harris, Andrew Haddon Kemp · 2012 · Journal of the International Neuropsychological Society
  29. Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: Findings from the CO-MED trial
    Bharathi Shrikanth Gadad, Manish K. Jha, Bruce D. Grannemann, Taryn L. Mayes, Madhukar H. Trivedi · 2017 · Journal of Psychiatric Research
  30. Nitric oxide involvement in depression during interferon-alpha therapy
    Eiji Suzuki, Yoshiko Yoshida, Akitaka Shibuya, Hitoshi Miyaoka · 2003 · The International Journal of Neuropsychopharmacology
  31. Inflammatory insults and mental health consequences: does timing matter when it comes to depression?
    Andrea Du Preez, J. Leveson, Patricia A. Zunszain, Carmine Maria Pariante · 2016 · Psychological Medicine
  32. Central Interleukin-1βSuppresses the Nocturnal Secretion of Melatonin
    Andrzej Przemysław Herman, Joanna Bochenek, Karolina Król, Agata Krawczyńska, Hanna Antushevich, Bartosz Pawlina, Andrzej Przemysław Herman, Katarzyna Romanowicz, Dorota Tomaszewska-Zaremba · 2016 · Mediators of Inflammation
  33. Enhanced norepinephrine output during long-term desipramine treatment: a possible role for the extraneuronal monoamine transporter (SLC22A3).
    J. Mooney, J. A. Samson, J. Hennen, Kathleen M. Pappalardo, N. McHale, J. Alpert, M. Koutsos, J. Schildkraut · 2008 · Journal of Psychiatric Research
  34. Mentally Sick or Not—(Bio)Markers of Psychiatric Disorders Needed
    Napoleon Waszkiewicz · 2020 · Journal of Clinical Medicine
  35. The DST in psychotic depression: diagnostic and pathophysiologic implications.
    Alan F. Schatzberg, Anthony J. Rothschild, Thomas C. Bond, Jonathan O Cole · 1984 · PubMed
  36. Desipramine does not alter plasma GABA in patients with major depression
    Frederick Petty, Joel L. Steinberg, Gerald L. Kramer, Mark Fulton, Frederick Gerard Moeller · 1993 · Journal of Affective Disorders
  37. Psychiatric Conditions in Parkinson Disease
    Massimiliano Buoli, Alice Caldiroli, Alfredo Carlo Altamura · 2015 · Journal of Geriatric Psychiatry and Neurology
  38. Serum haptoglobin levels in patients with melancholic and nonmelancholic major depression
    Murat Erdem, Cemil Çelik, Tuncer Çaycı, B. Handan Özdemir, Yasemin Gülcan Kurt, Emin Özgür Akgül, Halıl Yaman, Adem Balıkçı, Özcan Uzun · 2011 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  39. The role of interleukin genes in the course of depression
    Monika Ewa Talarowska, Janusz Szemraj, Piotr Gałecki · 2016 · Open Medicine
  40. Immunity and psychiatric disorders: variabilities of immunity biomarkers are they specific?
    Thomas Dubois, Christine Reynaert, Denis Jacques, Brice Lepièce, Pierre Patigny, Nicolas Zdanowicz · 2018 · PubMed
  41. Hyper-Insulin Response in a Patient With Depression: Changes in insulin resistance during recovery from depression
    Atsushi Tashiro, Michio Hongo, Ryoichi Ota, Atsushi Utsumi, Towako Imai · 1997 · Diabetes Care
  42. The biological face of melancholia: Are there any reliable biomarkers for this depression subtype?
    Cecilia Maria Esposito, Massimiliano Buoli · 2020 · Journal of Affective Disorders
  43. Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome
    Michael Cronquist Christensen, Vicki Munro · 2017 · Current Medical Research and Opinion
  44. The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes
    Michael S. Ritsner · 2009 · Springer eBooks
  45. Glutamine, glutamate and pyroglutamate — facts and fantasies
    GEORGE K. GRIMBLE · 1993 · Clinical Nutrition
  46. Lower angiotensin I converting enzyme activity in melancholic subjects: A pilot study
    Michael H. J. Maes, Simon Scharpé, Herbert Y. Meltzer, Eduard Suy, Paul R. Cosyns, Joseph R. Calabrese · 1992 · Biological Psychiatry
  47. Biomarkers for Major Depressive Disorder: Economic Considerations
    Nataša Bogavac‐Stanojević, Dragana Lakić · 2016 · Drug Development Research
  48. Interactome Studies of Psychiatric Disorders
    Dong Ik Park, Christoph W. Turck · 2019 · Advances in experimental medicine and biology
  49. Telomeres and depression
    Siân Lewis · 2014 · Nature reviews. Neuroscience
  50. Depressive symptoms, monoamines levels, MAO-B activity and effect of treatment in a subset of depressed individuals from government sector hospital at Karachi
    Farah Zeb, Sabira Naqvi, Razaur Rahman, Ahsana Dar Farooq · 2017 · Pakistan Journal of Pharmaceutical Sciences
  51. Microcircuits unmasked
    Darran M. Yates · 2014 · Nature reviews. Neuroscience